1. Home
  2. JFR vs ARDX Comparison

JFR vs ARDX Comparison

Compare JFR & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Floating Rate Income Fund

JFR

Nuveen Floating Rate Income Fund

HOLD

Current Price

$7.65

Market Cap

1.2B

Sector

Finance

ML Signal

HOLD

Logo Ardelyx Inc.

ARDX

Ardelyx Inc.

HOLD

Current Price

$3.83

Market Cap

996.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JFR
ARDX
Founded
2004
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
996.8M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
JFR
ARDX
Price
$7.65
$3.83
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$15.14
AVG Volume (30 Days)
555.8K
4.8M
Earning Date
01-01-0001
04-30-2026
Dividend Yield
11.31%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,607,000.00
Revenue This Year
N/A
$37.75
Revenue Next Year
N/A
$34.24
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.16
$3.73
52 Week High
$8.45
$8.40

Technical Indicators

Market Signals
Indicator
JFR
ARDX
Relative Strength Index (RSI) 46.54 27.50
Support Level $7.60 N/A
Resistance Level $7.67 $6.47
Average True Range (ATR) 0.05 0.14
MACD -0.01 0.01
Stochastic Oscillator 33.09 12.33

Price Performance

Historical Comparison
JFR
ARDX

About JFR Nuveen Floating Rate Income Fund

Nuveen Floating Rate Income Fund is a diversified closed-end management investment company. Its investment objective is to achieve a high level of current income. The fund invests a majority of its managed assets in secured Senior Loans and unsecured Senior Loans, with an average duration of one year or less, in which unsecured Senior Loans will be, at the time of investment, investment grade quality.

About ARDX Ardelyx Inc.

Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

Share on Social Networks: